Which has stronger valuation & earnings, OMCL or SGHT?

Omnicell has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omnicell $1.18B 1.27 $2.05M $0.84 39.38 Sight Sciences $83.38M 5.65 -$38.43M -$0.56 N/A

Is OMCL or SGHT more profitable?

Omnicell has a net margin of 3.13% compared to Sight Sciences' net margin of -35.69%. Omnicell's return on equity of 5.66% beat Sight Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Omnicell 3.13% 5.66% 3.57% Sight Sciences -35.69% -43.39% -22.86%

Is ATEC or SGHT more profitable?

Alphatec has a net margin of -13.49% compared to Sight Sciences' net margin of -35.69%. Sight Sciences' return on equity of -43.39% beat Alphatec's return on equity. Company Net Margins Return on Equity Return on Assets Alphatec -13.49% -6,752.24% -13.88% Sight Sciences -35.69% -43.39% -22.86%

Sight Sciences (SGHT) Competitors

$8.55 +0.14 (+1.66%)

As of 08/28/2026 04:00 PM Eastern

Compare

SGHT vs. OMCL, INSP, KMTS, TNDM, and ATEC

Should you buy Sight Sciences stock or one of its competitors? Sight Sciences's main competitors and comparable companies include Omnicell (OMCL), Inspire Medical Systems (INSP), Kestra Medical Technologies (KMTS), Tandem Diabetes Care (TNDM), and Alphatec (ATEC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Sight Sciences compare to Omnicell?

Omnicell (NASDAQ:OMCL) and Sight Sciences (NASDAQ:SGHT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

In the previous week, Omnicell had 6 more articles in the media than Sight Sciences. MarketBeat recorded 7 mentions for Omnicell and 1 mentions for Sight Sciences. Sight Sciences' average media sentiment score of 1.61 beat Omnicell's score of 1.45 indicating that Sight Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Omnicell	Positive
Sight Sciences	Very Positive

Omnicell presently has a consensus price target of $57.86, suggesting a potential upside of 74.90%. Sight Sciences has a consensus price target of $7.88, suggesting a potential downside of 7.89%. Given Omnicell's stronger consensus rating and higher probable upside, analysts plainly believe Omnicell is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Sight Sciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Omnicell has a net margin of 3.13% compared to Sight Sciences' net margin of -35.69%. Omnicell's return on equity of 5.66% beat Sight Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	3.13%	5.66%	3.57%
Sight Sciences	-35.69%	-43.39%	-22.86%

97.7% of Omnicell shares are owned by institutional investors. Comparatively, 55.5% of Sight Sciences shares are owned by institutional investors. 2.9% of Omnicell shares are owned by insiders. Comparatively, 30.4% of Sight Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Omnicell has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18B	1.27	$2.05M	$0.84	39.38
Sight Sciences	$83.38M	5.65	-$38.43M	-$0.56	N/A

Omnicell has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.38, meaning that its stock price is 138% more volatile than the broader market.

Summary

Omnicell beats Sight Sciences on 12 of the 16 factors compared between the two stocks.

How does Sight Sciences compare to Inspire Medical Systems?

Inspire Medical Systems (NYSE:INSP) and Sight Sciences (NASDAQ:SGHT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Inspire Medical Systems has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.38, indicating that its stock price is 138% more volatile than the broader market.

94.9% of Inspire Medical Systems shares are owned by institutional investors. Comparatively, 55.5% of Sight Sciences shares are owned by institutional investors. 2.2% of Inspire Medical Systems shares are owned by insiders. Comparatively, 30.4% of Sight Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Inspire Medical Systems currently has a consensus target price of $66.19, suggesting a potential upside of 7.64%. Sight Sciences has a consensus target price of $7.88, suggesting a potential downside of 7.89%. Given Inspire Medical Systems' higher possible upside, research analysts clearly believe Inspire Medical Systems is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspire Medical Systems	3 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.21
Sight Sciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Inspire Medical Systems has a net margin of 15.03% compared to Sight Sciences' net margin of -35.69%. Inspire Medical Systems' return on equity of 8.64% beat Sight Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inspire Medical Systems	15.03%	8.64%	7.45%
Sight Sciences	-35.69%	-43.39%	-22.86%

Inspire Medical Systems has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Inspire Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspire Medical Systems	$911.98M	1.95	$145.42M	$4.62	13.31
Sight Sciences	$83.38M	5.65	-$38.43M	-$0.56	N/A

In the previous week, Inspire Medical Systems had 8 more articles in the media than Sight Sciences. MarketBeat recorded 9 mentions for Inspire Medical Systems and 1 mentions for Sight Sciences. Inspire Medical Systems' average media sentiment score of 1.69 beat Sight Sciences' score of 1.61 indicating that Inspire Medical Systems is being referred to more favorably in the media.

Company	Overall Sentiment
Inspire Medical Systems	Very Positive
Sight Sciences	Very Positive

Summary

Inspire Medical Systems beats Sight Sciences on 12 of the 17 factors compared between the two stocks.

How does Sight Sciences compare to Kestra Medical Technologies?

Kestra Medical Technologies (NASDAQ:KMTS) and Sight Sciences (NASDAQ:SGHT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Sight Sciences has a net margin of -35.69% compared to Kestra Medical Technologies' net margin of -138.35%. Sight Sciences' return on equity of -43.39% beat Kestra Medical Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kestra Medical Technologies	-138.35%	-57.38%	-41.10%
Sight Sciences	-35.69%	-43.39%	-22.86%

Kestra Medical Technologies presently has a consensus price target of $28.14, suggesting a potential upside of 9.76%. Sight Sciences has a consensus price target of $7.88, suggesting a potential downside of 7.89%. Given Kestra Medical Technologies' higher possible upside, research analysts plainly believe Kestra Medical Technologies is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kestra Medical Technologies	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Sight Sciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

55.5% of Sight Sciences shares are held by institutional investors. 5.3% of Kestra Medical Technologies shares are held by insiders. Comparatively, 30.4% of Sight Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Sight Sciences has lower revenue, but higher earnings than Kestra Medical Technologies. Sight Sciences is trading at a lower price-to-earnings ratio than Kestra Medical Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kestra Medical Technologies	$95.13M	15.79	-$131.61M	-$2.42	N/A
Sight Sciences	$83.38M	5.65	-$38.43M	-$0.56	N/A

In the previous week, Kestra Medical Technologies had 2 more articles in the media than Sight Sciences. MarketBeat recorded 3 mentions for Kestra Medical Technologies and 1 mentions for Sight Sciences. Sight Sciences' average media sentiment score of 1.61 beat Kestra Medical Technologies' score of 0.62 indicating that Sight Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Kestra Medical Technologies	Positive
Sight Sciences	Very Positive

Kestra Medical Technologies has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.38, suggesting that its share price is 138% more volatile than the broader market.

Summary

Sight Sciences beats Kestra Medical Technologies on 11 of the 16 factors compared between the two stocks.

How does Sight Sciences compare to Tandem Diabetes Care?

Tandem Diabetes Care (NASDAQ:TNDM) and Sight Sciences (NASDAQ:SGHT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

In the previous week, Tandem Diabetes Care had 3 more articles in the media than Sight Sciences. MarketBeat recorded 4 mentions for Tandem Diabetes Care and 1 mentions for Sight Sciences. Tandem Diabetes Care's average media sentiment score of 1.63 beat Sight Sciences' score of 1.61 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company	Overall Sentiment
Tandem Diabetes Care	Very Positive
Sight Sciences	Very Positive

Tandem Diabetes Care has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.38, indicating that its share price is 138% more volatile than the broader market.

55.5% of Sight Sciences shares are owned by institutional investors. 2.1% of Tandem Diabetes Care shares are owned by insiders. Comparatively, 30.4% of Sight Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Tandem Diabetes Care currently has a consensus target price of $28.98, indicating a potential upside of 35.21%. Sight Sciences has a consensus target price of $7.88, indicating a potential downside of 7.89%. Given Tandem Diabetes Care's higher possible upside, equities analysts clearly believe Tandem Diabetes Care is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.48
Sight Sciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Sight Sciences has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Sight Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.01B	1.47	-$204.71M	-$0.93	N/A
Sight Sciences	$83.38M	5.65	-$38.43M	-$0.56	N/A

Tandem Diabetes Care has a net margin of -6.08% compared to Sight Sciences' net margin of -35.69%. Sight Sciences' return on equity of -43.39% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-6.08%	-45.97%	-6.23%
Sight Sciences	-35.69%	-43.39%	-22.86%

Summary

Sight Sciences beats Tandem Diabetes Care on 9 of the 17 factors compared between the two stocks.

How does Sight Sciences compare to Alphatec?

Alphatec (NASDAQ:ATEC) and Sight Sciences (NASDAQ:SGHT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

Sight Sciences has lower revenue, but higher earnings than Alphatec. Sight Sciences is trading at a lower price-to-earnings ratio than Alphatec, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alphatec	$815.05M	1.79	-$143.36M	-$0.71	N/A
Sight Sciences	$83.38M	5.65	-$38.43M	-$0.56	N/A

Alphatec has a net margin of -13.49% compared to Sight Sciences' net margin of -35.69%. Sight Sciences' return on equity of -43.39% beat Alphatec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alphatec	-13.49%	-6,752.24%	-13.88%
Sight Sciences	-35.69%	-43.39%	-22.86%

Alphatec has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.38, suggesting that its stock price is 138% more volatile than the broader market.

In the previous week, Alphatec had 1 more articles in the media than Sight Sciences. MarketBeat recorded 2 mentions for Alphatec and 1 mentions for Sight Sciences. Alphatec's average media sentiment score of 1.71 beat Sight Sciences' score of 1.61 indicating that Alphatec is being referred to more favorably in the media.

Company	Overall Sentiment
Alphatec	Very Positive
Sight Sciences	Very Positive

Alphatec presently has a consensus target price of $17.40, indicating a potential upside of 84.32%. Sight Sciences has a consensus target price of $7.88, indicating a potential downside of 7.89%. Given Alphatec's stronger consensus rating and higher possible upside, analysts plainly believe Alphatec is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alphatec	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Sight Sciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

66.3% of Alphatec shares are held by institutional investors. Comparatively, 55.5% of Sight Sciences shares are held by institutional investors. 13.5% of Alphatec shares are held by company insiders. Comparatively, 30.4% of Sight Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Alphatec beats Sight Sciences on 10 of the 16 factors compared between the two stocks.

Get Sight Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGHT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGHT vs. The Competition

Export

Metric	Sight Sciences	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$471.00M	$5.88B	$7.21B	$12.90B
Dividend Yield	N/A	1.75%	2.54%	11.28%
P/E Ratio	-15.27	21.48	212.62	21.91
Price / Sales	5.65	68.66	625.86	92.63
Price / Cash	N/A	33.69	28.74	36.03
Price / Book	7.07	6.18	11.08	6.36
Net Income	-$38.43M	$149.94M	$3.48B	$349.79M
7 Day Performance	3.51%	-0.24%	0.13%	-0.80%
1 Month Performance	62.55%	6.18%	7.08%	4.13%
1 Year Performance	110.59%	6.30%	24.67%	15.17%

Sight Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGHT Sight Sciences	1.6974 of 5 stars	$8.55 +1.7%	$7.88 -7.9%	+110.6%	$471.00M	$83.38M	N/A	210	Positive News
OMCL Omnicell	4.3 of 5 stars	$35.97 -0.2%	$57.86 +60.8%	+1.5%	$1.70B	$1.18B	42.82	3,580	Positive News
INSP Inspire Medical Systems	3.4067 of 5 stars	$57.43 +0.4%	$66.19 +15.3%	-34.5%	$1.65B	$911.98M	12.43	1,333	Positive News
KMTS Kestra Medical Technologies	1.7943 of 5 stars	$27.93 +0.4%	$28.14 +0.8%	+58.9%	$1.63B	$95.13M	N/A	300
TNDM Tandem Diabetes Care	3.5384 of 5 stars	$23.73 +6.7%	$28.98 +22.1%	+71.3%	$1.58B	$1.01B	N/A	2,500	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGHT) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sight Sciences (SGHT) Competitors

SGHT vs. OMCL, INSP, KMTS, TNDM, and ATEC

How does Sight Sciences compare to Omnicell?

Summary

How does Sight Sciences compare to Inspire Medical Systems?

Summary

How does Sight Sciences compare to Kestra Medical Technologies?

Summary

How does Sight Sciences compare to Tandem Diabetes Care?

Summary

How does Sight Sciences compare to Alphatec?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGHT vs. The Competition

Sight Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sight Sciences (SGHT) Competitors

SGHT vs. OMCL, INSP, KMTS, TNDM, and ATEC

How does Sight Sciences compare to Omnicell?

Does the media prefer OMCL or SGHT?

Do analysts rate OMCL or SGHT?

Is OMCL or SGHT more profitable?

Do insiders & institutionals have more ownership in OMCL or SGHT?

Which has stronger valuation & earnings, OMCL or SGHT?

Which has more risk & volatility, OMCL or SGHT?

Summary

How does Sight Sciences compare to Inspire Medical Systems?

Which has more risk and volatility, INSP or SGHT?

Do insiders and institutionals have more ownership in INSP or SGHT?

Do analysts recommend INSP or SGHT?

Is INSP or SGHT more profitable?

Which has higher valuation and earnings, INSP or SGHT?

Does the media refer more to INSP or SGHT?

Summary

How does Sight Sciences compare to Kestra Medical Technologies?

Is KMTS or SGHT more profitable?

Do analysts recommend KMTS or SGHT?

Do institutionals and insiders have more ownership in KMTS or SGHT?

Which has stronger valuation & earnings, KMTS or SGHT?

Does the media favor KMTS or SGHT?

Which has more risk and volatility, KMTS or SGHT?

Summary

How does Sight Sciences compare to Tandem Diabetes Care?

Does the media favor TNDM or SGHT?

Which has more risk & volatility, TNDM or SGHT?

Do insiders and institutionals have more ownership in TNDM or SGHT?

Do analysts rate TNDM or SGHT?

Which has higher valuation and earnings, TNDM or SGHT?

Is TNDM or SGHT more profitable?

Summary

How does Sight Sciences compare to Alphatec?

Which has higher valuation and earnings, ATEC or SGHT?

Is ATEC or SGHT more profitable?

Which has more volatility & risk, ATEC or SGHT?

Does the media refer more to ATEC or SGHT?

Do analysts recommend ATEC or SGHT?

Do institutionals & insiders have more ownership in ATEC or SGHT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGHT vs. The Competition

Sight Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools